Redsense Medical announces that the publication of the interim report for the first quarter of 2025 will take place on 28 May 2025, instead of the previously communicated date of 14 May 2025.

Historically, the company has published its Q1 report on the same day as its Annual General Meeting to ensure consistent and transparant information disclosure. As the 2025 Annual General Meeting has been rescheduled to 28 May, the publication date of the Q1 report is being adjusted accordingly.

The interim report for the first quarter of 2025 will be published on 28 May 2025 at 08:00.

Contact information

For more information, please contact: 
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS).